13F-HR/A filed by Venrock Adviser, LLC
Venrock Adviser, LLC filed this 13F-HR/A for the quarter ended 2022-06-30, filed 2023-05-15, with 27 holding rows worth $507,777,000.
- Accession
- 0001104659-23-060779
- Filer
- CIK 1615982
- Filed
- 2023-05-15
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q2 2022
A holdings report, amendment of type restatement, 27 entries on the cover page, a total value of $507,777,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $507,777,000 with VALUE read as dollars as filed, 13F file number 028-20281. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| TRICIDA INC | 89610F101 | COM | 7,132,079 | $69,039,000 | dollars as filed | |
| ACLARIS THERAPEUTICS INC COM | 00461U105 | Stock | 4,563,962 | $63,713,000 | dollars as filed | |
| RELMADA THERAPEUTICS INC | 75955J402 | COMMON STOCK | 2,270,072 | $43,109,000 | dollars as filed | |
| TRAVERE THERAPEUTICS INC | 89422G107 | COM | 1,711,102 | $41,460,000 | dollars as filed | |
| COGENT BIOSCIENCES INC | 19240Q201 | COM | 4,038,117 | $36,424,000 | dollars as filed | |
| GH RESEARCH PLC ORDINARY SHARES | G3855L106 | Stock | 3,185,573 | $31,792,000 | dollars as filed | |
| Instil Bio, Inc. | 45783C101 | Common Stock | 5,997,657 | $27,709,000 | dollars as filed | |
| CELLDEX THERAPEUTICS INC NEW | 15117B202 | COM NEW | 865,116 | $23,324,000 | dollars as filed | |
| VIRIDIAN THERAPEUTICS INC | 92790C104 | COM | 1,852,919 | $21,438,000 | dollars as filed | |
| VISTAGEN THERAPEUTICS INC | 92840H202 | COM | 20,697,286 | $18,214,000 | dollars as filed | |
| MARINUS PHARMACEUTICALS INC | 56854Q200 | COM NEW | 3,156,803 | $15,279,000 | dollars as filed | |
| WHITEHAWK THERAPEUTICS INC | 00032Q104 | CMN | 1,173,518 | $14,458,000 | dollars as filed | |
| INOZYME PHARMA INC | 45790W108 | COM | 2,709,987 | $12,927,000 | dollars as filed | |
| AKOUOS INC | 00973J101 | COM | 2,667,119 | $12,509,000 | dollars as filed | |
| LIANBIO ADR | 53000N108 | COM | 5,378,341 | $11,617,000 | dollars as filed | |
| AEROVATE THERAPEUTICS INC | 008064107 | COM | 590,408 | $9,228,000 | dollars as filed | |
| TREVI THERAPEUTICS INC COM | 89532M101 | Stock | 3,050,022 | $8,571,000 | dollars as filed | |
| CHINOOK THERAPEUTICS INC | 16961L106 | COM | 489,618 | $8,563,000 | dollars as filed | |
| ANNEXON INC | 03589W102 | COM | 1,928,477 | $7,270,000 | dollars as filed | |
| SAVARA INC | 805111101 | COM | 4,117,530 | $6,259,000 | dollars as filed | |
| LYRA THERAPEUTICS INC | 55234L105 | COM | 924,170 | $5,222,000 | dollars as filed | |
| PROVENTION BIO INC | 74374N102 | COM | 1,118,653 | $4,475,000 | dollars as filed | |
| ALTIMMUNE INC | 02155H200 | COM NEW | 369,306 | $4,321,000 | dollars as filed | |
| ATYR PHARMA INC | 002120202 | COM NEW | 1,398,889 | $3,959,000 | dollars as filed | |
| AFFIMED N V | N01045108 | COM | 1,428,571 | $3,957,000 | dollars as filed | |
| RALLYBIO CORP | 75120L100 | COM | 268,532 | $2,027,000 | dollars as filed | |
| XENON PHARMACEUTICALS INC COM | 98420N105 | Stock | 30,000 | $913,000 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001104659-22-091231 | superseded | 2022-08-15 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001104659-23-060779 | this filing | 2023-05-15 | acceptance time not in the bulk data set |